[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018010334A - Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). - Google Patents

Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).

Info

Publication number
MX2018010334A
MX2018010334A MX2018010334A MX2018010334A MX2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A
Authority
MX
Mexico
Prior art keywords
compound
inhibiting activity
jak
crystal
effect
Prior art date
Application number
MX2018010334A
Other languages
English (en)
Inventor
Higuchi Fumi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2018010334A publication Critical patent/MX2018010334A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un objeto de la presente invención es proporcionar un compuesto con una excelente actividad inhibidora de JAK1. El compuesto de la invención tiene actividad inhibidora de JAK1, y por lo tanto, efecto inmunosupresor, efecto antiinflamatorio, efecto antiproliferativo, etc., y es útil en el tratamiento de las enfermedades, por ejemplo, artritis reumatoide, enfermedad inflamatoria intestinal, psoriasis, vasculitis, asma bronquial, enfermedad pulmonar obstructiva crónica, sinusitis eosinofílica y pólipo nasal.
MX2018010334A 2016-03-01 2017-02-28 Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). MX2018010334A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016039315 2016-03-01
PCT/JP2017/007594 WO2017150477A1 (ja) 2016-03-01 2017-02-28 Ｊａｋ阻害作用を有する化合物の結晶

Publications (1)

Publication Number Publication Date
MX2018010334A true MX2018010334A (es) 2018-11-09

Family

ID=59743962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010334A MX2018010334A (es) 2016-03-01 2017-02-28 Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).

Country Status (21)

Country Link
US (2) US10822350B2 (es)
EP (1) EP3424930B1 (es)
JP (1) JP6791239B2 (es)
KR (1) KR102653231B1 (es)
CN (1) CN108699082B (es)
BR (1) BR112018016523B1 (es)
CA (2) CA3206830A1 (es)
CY (1) CY1123607T1 (es)
DK (1) DK3424930T3 (es)
ES (1) ES2844978T3 (es)
HR (1) HRP20210062T1 (es)
HU (1) HUE051615T2 (es)
LT (1) LT3424930T (es)
MX (1) MX2018010334A (es)
PL (1) PL3424930T3 (es)
PT (1) PT3424930T (es)
RS (1) RS61238B1 (es)
RU (1) RU2705721C1 (es)
SI (1) SI3424930T1 (es)
TW (1) TWI712604B (es)
WO (1) WO2017150477A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
WO2022053660A2 (en) * 2020-09-14 2022-03-17 Eurochem Antwerpen N-heterocyclic compounds used as nitrification inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
US8580802B2 (en) * 2005-09-30 2013-11-12 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
BRPI0722364A2 (pt) 2006-01-17 2011-08-16 Vertex Pharma azaindóis, composição farmacêutica e usos dos referidos compostos
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
CA2782720A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CA2812088A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
EP2629777B1 (en) 2010-10-22 2018-12-19 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶

Also Published As

Publication number Publication date
BR112018016523A2 (pt) 2018-12-26
JPWO2017150477A1 (ja) 2018-12-27
EP3424930A1 (en) 2019-01-09
US10822350B2 (en) 2020-11-03
KR20180116341A (ko) 2018-10-24
TW201731855A (zh) 2017-09-16
BR112018016523B1 (pt) 2024-02-06
CA3206830A1 (en) 2017-09-08
PL3424930T3 (pl) 2021-05-04
CN108699082A (zh) 2018-10-23
RS61238B1 (sr) 2021-01-29
CN108699082B (zh) 2021-04-09
CA3015464A1 (en) 2017-09-08
US11377453B2 (en) 2022-07-05
US20190048023A1 (en) 2019-02-14
HRP20210062T1 (hr) 2021-03-05
TWI712604B (zh) 2020-12-11
SI3424930T1 (sl) 2021-01-29
JP6791239B2 (ja) 2020-11-25
DK3424930T3 (da) 2021-01-11
US20210017191A1 (en) 2021-01-21
HUE051615T2 (hu) 2021-03-01
EP3424930B1 (en) 2020-11-04
LT3424930T (lt) 2021-01-11
ES2844978T3 (es) 2021-07-23
CY1123607T1 (el) 2022-03-24
RU2705721C1 (ru) 2019-11-11
PT3424930T (pt) 2020-12-04
CA3015464C (en) 2024-04-23
EP3424930A4 (en) 2019-07-10
KR102653231B1 (ko) 2024-04-01
WO2017150477A1 (ja) 2017-09-08

Similar Documents

Publication Publication Date Title
PH12015501713B1 (en) Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP3694500A4 (en) TREATMENT OF INFLAMMATORY DISORDERS
EA201400729A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ГЛИТАЗОНЫ И Nrf2 АКТИВАТОРЫ
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
CL2016002888A1 (es) Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras.
NZ720660A (en) Apoptosis signal-regulating kinase inhibitors
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EA201491786A1 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
NZ629728A (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
EA201590721A1 (ru) Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
JO3458B1 (ar) 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CY1123320T1 (el) Ενωση πυραζολοθειαζολης και φαρμακο που την περιλαμβανει
MX2021008819A (es) Analogos de cisteamina resistentes a la ado y sus usos.
EP3735248A4 (en) PROCESS FOR INHIBITED OR ELIMINATING EOSINOPHILIC DISEASES OF THE RESPIRATORY TRACT AND ASSOCIATED CONDITIONS
MX2018010334A (es) Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).
EP3504178A4 (en) COMPOSITIONS AND METHODS RELATING TO THE PRODUCTION OF ACRYLNITRILE
MX2012014983A (es) Quinolinas como inhibidores pi3k.
TR201905319T4 (tr) Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri.
EP3247761A4 (en) Use of hydroxyacid to reduce the localized corrosion potential of low dose hydrate inhibitors
BR112017004163A2 (pt) método de tratamento e composições com um inibidor de quinase pi3k delta e gamma duplo e um corticostoide
EP3383415A4 (en) USE OF MITOCHONDRIAL IRON RADIATORS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE
AU2019900851A0 (en) Treatment of Inflammatory Disorders
EP3694521A4 (en) TOPICAL METHOTREXATE SOLUTION FOR TREATMENT OF PSORIASIS
MX370251B (es) Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades.
GB201809005D0 (en) Compositions and methods realting to the treatment of psoriasis